Premium
Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR*D trial
Author(s) -
Bech P.,
Fava M.,
Trivedi M. H.,
Wisniewski S. R.,
Rush A. J.
Publication year - 2012
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1111/j.1600-0447.2011.01791.x
Subject(s) - bupropion , citalopram , buspirone , psychology , depression (economics) , antidepressant , psychiatry , medicine , anxiety , smoking cessation , receptor , macroeconomics , pathology , economics , agonist
Bech P, Fava M, Trivedi MH, Wisniewski SR, Rush AJ. Outcomes on the pharmacopsychometric triangle in bupropion‐SR vs. buspirone augmentation of citalopram in the STAR*D trial. Objective: To compare within the framework of a novel pharmacopsychometric triangle, augmentation treatment with bupropion vs. buspirone in the acute therapy of major depression in the STAR*D study. The triangle provides a composite view in three domains of antidepressive activity, side effects, and quality of life. Method: Within the pharmacopsychometric triangle, the short six‐item subscales of the Hamilton Depression Scale (HAM‐D 17 ) and of the Inventory of Depressive Symptomatology (IDS‐C 30 ), referred to as HAM‐D 6 and IDS‐C 6 , were focussed on pure antidepressive effect. Side‐effects (tolerable vs. intolerable) and quality of life were measured using patient‐administered questionnaires. A modified intention to treat sample was used. Results: Within the pharmacopsychometric triangle, bupropion‐SR (sustained release) was superior to buspirone when augmented to the current citalopram treatment. Thus, in the domain of pure antidepressive effect, bupropion‐SR was superior ( P = 0.05) on the HAM‐D 6 , IDS‐C 6 , and IDS‐C 30 , but not on the HAM‐D 17 . In the domain of side effects, the total scores on the Patient Rated Inventory of Side Effects (PRISE) were reduced significantly more by bupropion‐SR than by buspirone ( P = 0.03). In the domain of quality of life, the total scores on the Quality of Life Enjoyment and Satisfaction Questionnaire (QLES‐Q) showed a trend ( P = 0.10) from baseline to endpoint of a superiority for bupropion‐SR compared with buspirone. Conclusion: In all domains of the pharmacopsychometric triangle, bupropion‐SR was superior to buspirone as augmentation therapy in depressed outpatients not responding to citalopram.